Efgartigimod vs IVIG: Myasthenic Crisis Treatment Study

Summary of the Research on Efgartigimod vs. IVIG for ‍Myasthenia ⁣Gravis

This text details a retrospective cohort study comparing the efficacy and safety of efgartigimod to intravenous immunoglobulin (IVIG) in patients with⁤ acetylcholine receptor antibody-positive myasthenia gravis (MG) who were at ‍risk of myasthenic crisis. Here’s a breakdown of the key findings:

Key Results:

* MG-ADL & ‍QMG Scores: ⁣Efgartigimod ⁢consistently showed greater advancement in both MG-ADL (Myasthenia Gravis activities of Daily Living) and QMG (Quantitative Myasthenia Gravis) scores‍ compared to IVIG across the four weeks studied. Specific data points include:
* Week 1: MG-ADL: 13.30 (3.86) vs 13.60 (2.06); QMG: 9.50 (3.03) vs 12.80 (2.65)
* Week 4: MG-ADL: 7.73 (3.20)⁢ vs 11.85 (4.97); QMG: 8.30 (3.23) vs NA (for IVIG)
* Significant Improvement Rates: A higher percentage of patients treated with efgartigimod experienced significant improvement (≥2 points on MG-ADL and ≥5 points on QMG) at both week ⁢1‍ and week 4.
* MG-ADL: 83.3% vs 71.4% (Week 1); 96.7% vs 85.7% (Week 4)
⁤ * QMG: 70.0% vs 47.6% (Week 1);⁤ 96.7% vs 71.4% (Week 4)
* Hospital Stay: Patients ⁢receiving efgartigimod had a shorter length of hospital stay.
* Myasthenic Crisis: ‍ No patients treated with efgartigimod progressed to myasthenic crisis, while one patient in the IVIG group did.
*⁤ Safety: efgartigimod was shown to be safe for patients.

Conclusion:

The authors conclude that the results provide strong evidence‍ supporting the clinical use of efgartigimod ‍for this patient population. It demonstrated significant clinical improvement, safety, and rapid symptom relief.

Limitations:

the study acknowledges several limitations:

* Confounding & Selection Bias: The retrospective nature of the study introduces the possibility of ‍these biases.
* Small Sample Size: The study involved a limited number of patients.
* Clinical Data Only: Conclusions ‍were based solely ⁢on clinical data, without other types of measurements.
* Specific Patient Group: The study only included patients with acetylcholine receptor ⁣antibody-positive MG.

Reference:

*⁤ Guo R, Sun C, ⁢Huang X, et al. Efficacy⁢ and safety of ‍efgartigimod versus intravenous⁣ immunoglobulin in early intervention of acetylcholine receptor antibody-positive⁢ impending myasthenic crisis:⁤ a retrospective cohort study. neurotherapeutics. Published⁢ online September 5, 2025. doi:10.1016/j.neurot.2025.e00730